One of the world's largest pharmaceutical companies, Merck KGaA (ETR: MRK), has reiterated its commitment to its partnership with the Ugandan government via its non-profit subsidiary Merck Foundation, Pharmafile reported on Tuesday.
The partnership aims to bolster the country's healthcare abilities and treatment access in the region, with a particular emphasis in areas concerning cancer, cardiovascular disease, diabetes and infertility.
The 'Merck more than a mother' project was first launched in 2012.
"Raising awareness about male infertility is very important to change the culture as [it] affects women and men equally and yet women are the one who been solely blamed, discriminated and mistreated in their communities," commented Merck Foundation CEO Dr Rasha Kelej.
"The campaign will address this topic and encourage men to discuss openly their infertility and share the journey of infertility diagnosis and treatment with their wives."
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment